Kulkarni Samarth's most recent trade in CRISPR Therapeutics AG was a trade of 100,000 shares done . Disclosure was reported to the exchange on Oct. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2026 | 100,000 | 359,736 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.78 per share. | 16 Oct 2026 | 47,837 | 311,899 (0%) | 0% | 49.8 | 2,381,326 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2026 | 8,333 | 263,834 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.26 per share. | 13 Oct 2026 | 4,098 | 259,736 (0%) | 0% | 49.3 | 201,867 | - |
| Black Diamond Therapeutics Inc | Dr. Samarth Kulkarni, PhD | Director | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jun 2026 | 208,474 | 0 | - | - | Share Option (right to buy) | |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jun 2026 | 48,000 | 0 | - | - | Share Option (right to buy) | |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jun 2026 | 48,000 | 0 | - | - | Share Option (right to buy) | |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jun 2026 | 48,000 | 0 | - | - | Share Option (right to buy) | |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jun 2026 | 40,000 | 0 | - | - | Share Option (right to buy) | |
| Oruka Therapeutics Inc | Dr. Samarth Kulkarni, PhD | Director | 02 Jun 2026 | 9,136 | 9,136 | - | - | Stock Option (right to buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2026 | 114,249 | 114,249 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2026 | 81,875 | 81,875 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 19,687 | 265,521 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2026 | 19,687 | 39,375 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 19,687 | 265,521 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 19,687 | 265,521 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.78 per share. | 20 Mar 2026 | 10,020 | 255,501 (0%) | 0% | 46.8 | 468,736 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.78 per share. | 20 Mar 2026 | 10,020 | 255,501 (0%) | 0% | 46.8 | 468,736 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.78 per share. | 20 Mar 2026 | 10,020 | 255,501 (0%) | 0% | 46.8 | 468,736 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 20,625 | 256,183 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 14 Mar 2026 | 20,625 | 61,875 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 20,625 | 256,183 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 20,625 | 256,183 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 10,349 | 245,834 (0%) | 0% | 48.3 | 499,443 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 10,349 | 245,834 (0%) | 0% | 48.3 | 499,443 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 10,349 | 245,834 (0%) | 0% | 48.3 | 499,443 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 19,250 | 245,356 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 10 Mar 2026 | 19,250 | 19,250 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 19,250 | 245,356 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 19,250 | 245,356 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 10 Mar 2026 | 9,798 | 235,558 (0%) | 0% | 52.8 | 517,334 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 10 Mar 2026 | 9,798 | 235,558 (0%) | 0% | 52.8 | 517,334 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 10 Mar 2026 | 9,798 | 235,558 (0%) | 0% | 52.8 | 517,334 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 13,250 | 233,073 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 18 Feb 2026 | 13,250 | 0 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 13,250 | 233,073 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 13,250 | 233,073 (0%) | 0% | - | - | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.58 per share. | 18 Feb 2026 | 6,967 | 226,106 (0%) | 0% | 52.6 | 366,325 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.58 per share. | 18 Feb 2026 | 6,967 | 226,106 (0%) | 0% | 52.6 | 366,325 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.58 per share. | 18 Feb 2026 | 6,967 | 226,106 (0%) | 0% | 52.6 | 366,325 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.23 per share. | 20 Jan 2026 | 60,000 | 134,201 (0%) | 0% | 60.2 | 3,613,800 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.23 per share. | 20 Jan 2026 | 60,000 | 134,201 (0%) | 0% | 60.2 | 3,613,800 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.23 per share. | 20 Jan 2026 | 60,000 | 134,201 (0%) | 0% | 60.2 | 3,613,800 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.61 per share. | 20 Jan 2026 | 21,433 | 202,768 (0%) | 0% | 51.6 | 1,106,157 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.61 per share. | 20 Jan 2026 | 21,433 | 202,768 (0%) | 0% | 51.6 | 1,106,157 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.61 per share. | 20 Jan 2026 | 21,433 | 202,768 (0%) | 0% | 51.6 | 1,106,157 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.10 per share. | 20 Jan 2026 | 8,567 | 194,201 (0%) | 0% | 52.1 | 446,341 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.10 per share. | 20 Jan 2026 | 8,567 | 194,201 (0%) | 0% | 52.1 | 446,341 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.10 per share. | 20 Jan 2026 | 8,567 | 194,201 (0%) | 0% | 52.1 | 446,341 | - |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2025 | 30,000 | 224,201 (0%) | 0% | 0 | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2025 | 100,000 | 305,096 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 16 Oct 2025 | 100,000 | 300,000 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.91 per share. | 16 Oct 2025 | 50,895 | 254,201 (0%) | 0% | 67.9 | 3,456,279 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 13 Oct 2025 | 8,334 | 8,333 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 8,334 | 209,338 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.60 per share. | 13 Oct 2025 | 4,242 | 205,096 (0%) | 0% | 66.6 | 282,517 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 03 Oct 2025 | 49,500 | 49,500 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Sep 2025 | 6,000 | 201,004 (0%) | 0% | 0 | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 16 Aug 2025 | 25,000 | 0 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2025 | 25,000 | 220,085 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 58.15 per share. | 16 Aug 2025 | 13,081 | 207,004 (0%) | 0% | 58.1 | 760,660 | Common Shares |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 40,000 | 40,000 | - | - | Share Option (right to buy) | |
| Black Diamond Therapeutics Inc | Dr. Samarth Kulkarni, PhD | Director | 12 Jun 2025 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | ||
| Oruka Therapeutics Inc | Dr. Samarth Kulkarni, PhD | Director | 02 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2025 | 19,688 | 59,062 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 19,688 | 205,116 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 20 Mar 2025 | 10,031 | 195,085 (0%) | 0% | 41.2 | 413,578 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 14 Mar 2025 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 14 Mar 2025 | 82,500 | 82,500 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 19,250 | 190,863 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 10 Mar 2025 | 19,250 | 38,500 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.42 per share. | 10 Mar 2025 | 9,973 | 180,890 (0%) | 0% | 42.4 | 423,055 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 10 Mar 2025 | 9,000 | 0 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 9,000 | 189,890 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 10 Mar 2025 | 4,462 | 185,428 (0%) | 0% | 43.3 | 193,294 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.21 per share. | 19 Feb 2025 | 18,360 | 171,613 (0%) | 0% | 55.2 | 1,013,564 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 13,250 | 208,541 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 18 Feb 2025 | 13,250 | 13,250 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.05 per share. | 18 Feb 2025 | 11,640 | 196,901 (0%) | 0% | 55.1 | 640,782 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 18 Feb 2025 | 6,928 | 189,973 (0%) | 0% | 52.8 | 365,798 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.21 per share. | 24 Dec 2024 | 13,751 | 195,291 (0%) | 0% | 16.2 | 222,904 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 24 Dec 2024 | 13,751 | 0 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.10 per share. | 02 Dec 2024 | 15,000 | 181,540 (0%) | 0% | 55.1 | 826,565 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.43 per share. | 11 Nov 2024 | 23,121 | 203,419 (0%) | 0% | 55.4 | 1,281,597 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.27 per share. | 11 Nov 2024 | 6,879 | 196,540 (0%) | 0% | 56.3 | 387,081 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 16 Oct 2024 | 400,000 | 400,000 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 16 Oct 2024 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 13 Oct 2024 | 8,333 | 16,667 | - | - | Restricted Stock Units | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 8,333 | 230,833 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 13 Oct 2024 | 4,293 | 226,540 (0%) | 0% | 46.3 | 198,680 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Aug 2024 | 100,000 | 222,500 (0%) | 0% | 0 | Common Shares | |
| Centessa Pharma PLC (ADR) | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 48,000 | 48,000 | - | - | Share Option (right to buy) | |
| Repare Therapeutics Inc | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics Inc | Dr. Samarth Kulkarni, PhD | Director | 06 Jun 2024 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 15 Apr 2024 | 19,582 | 0 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 15 Apr 2024 | 19,582 | 227,704 (0%) | 0% | 19.1 | 374,408 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.88 per share. | 15 Apr 2024 | 18,378 | 209,326 (0%) | 0% | 59.9 | 1,100,510 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.40 per share. | 15 Apr 2024 | 1,204 | 208,122 (0%) | 0% | 60.4 | 72,722 | Common Shares |
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2024 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Dr. Samarth Kulkarni, PhD | Director, Chief Executive Officer | 20 Mar 2024 | 78,750 | 78,750 | - | - | Restricted Stock Units |